Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Investment Type: Venture Capital
Mentions in press and media 5
| Date | Title | Description | Source |
| 10.05.2021 | Alebund Pharmaceuticals Raises $60 million in Series B Finan... | SHANGHAI, May 10, 2021 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Com... | en.prnasia... |
| 26.07.2016 | Gates Foundation leads $14M funding round for Just Biotherap... | Just Biotherapeutics CEO and Founding Partner Jim Thomas Seattle-based Just Biotherapeutics said Mo... | geekwire.c... |
| 06.01.2016 | Daily funding roundup - January 6, 2016 | Flatiron Health bagged $175M; NextCure, Inc. raised $67M; AirCloset received $8M funding Ossia, a B... | vator.tv/n... |
| 29.10.2015 | MabSpace Biosciences Completes $15M Series A Financing | MabSpace Biosciences Co., Ltd., a Suzhou, China-based company focused on the discovery and developme... | finsmes.co... |
| 21.09.2015 | Daily funding roundup - September 21, 2015 | Deciphera bagged $75M; Portea raised $37.5M; Just Biotherapeutics secured $15M BidFlyer, an Israeli... | vator.tv/n... |